AEON Biopharma (AEON) Assets Average (2021 - 2026)
AEON Biopharma (AEON) posted Assets Average of $7.1 million for Q4 2025, down 29.92% sequentially from $10.2 million in Q3 2025, and up 100.03% YoY from $3.6 million in Q4 2024.
AEON Biopharma (AEON) Assets Average (2021 - 2026) Analysis & Trends
AEON Biopharma has reported Assets Average for 5 years, with the latest figure at $7.1 million in Q4 2025.
- Quarterly Assets Average rose 100.03% year-over-year to $7.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.1 million (up 100.03% YoY) and the FY2025 annual result came in at $4.4 million, down 12.87% from the prior year.
- Assets Average slipped to $7.1 million in Q4 2025 per AEON's latest filing, from $10.2 million in the prior quarter.
- Over five years, Assets Average peaked at $277.9 million in Q2 2021 and troughed at $3.6 million in Q4 2024.
- A 5-year average of $103.6 million and a median of $17.9 million in 2023 frame the typical range for Assets Average.
- The sharpest annual moves came in 2023 and 2025: Assets Average tumbled 94.15% in 2023, then jumped 190.45% in 2025.
- Over 5 years, Assets Average stood at $277.1 million in 2021, then tumbled by 48.01% to $144.1 million in 2022, then sank by 91.51% to $12.2 million in 2023, then tumbled by 70.79% to $3.6 million in 2024, then surged by 100.03% to $7.1 million in 2025.
- According to Business Quant data, Assets Average over the past three periods registered $7.1 million, $10.2 million, and $12.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | AEON Biopharma | 9.71 Mn | 6.28 Mn | - | 5.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.74 Mn |
| Dec 31, 2025 | 7.15 Mn |
| Sep 30, 2025 | 10.20 Mn |
| Jun 30, 2025 | 12.73 Mn |
| Mar 31, 2025 | 8.47 Mn |
| Dec 31, 2024 | 3.57 Mn |
| Sep 30, 2024 | 4.87 Mn |
| Jun 30, 2024 | 4.38 Mn |
| Mar 31, 2024 | 4.94 Mn |
| Dec 31, 2023 | 12.23 Mn |
| Sep 30, 2023 | 19.70 Mn |
| Jun 30, 2023 | 21.70 Mn |
| Mar 31, 2023 | 16.20 Mn |
| Dec 31, 2022 | 144.05 Mn |
| Sep 30, 2022 | 276.92 Mn |
| Jun 30, 2022 | 276.58 Mn |
| Mar 31, 2022 | 276.80 Mn |
| Dec 31, 2021 | 277.08 Mn |
| Sep 30, 2021 | 277.41 Mn |
| Jun 30, 2021 | 277.88 Mn |